| Name | Title | Contact Details |
|---|
We generate human-specific efficacy and safety data with pioneering PhysioMimix™ single- and multi-organ-on-a-chip solutions. Our advantage comes from having had almost unparalleled resources to invest in the development of leading edge organ-chips thanks to more than $32 Million in grants and contracts from DARPA, NIH, EU FP7, Innovate UK and NC3Rs. These programs have led to the development of a 7-organ human body-on-a-chip model (DARPA), a liver-on-a-chip model of cancer metastasis (NIH), a full viral lifecycle organ-chip model of hepatitis B and a liver-on-a-chip model of non-alcoholic fatty liver disease and steatohepatitis (NAFLD/NASH). CN Bio is at the forefront of translating these promising technologies from leading academic laboratories into the hands of pharmaceutical researchers for the development of new medicines to treat and cure disease and to the wider academic community seeking to understand biology and disease pathology using technologies which more closely represent the human response.
Denham Capital is an Energy and Resources Private Equity Firm Investing in Oil & Gas, Power and Mining with offices in Houston, London, Boston, and Perth.
Conservation X Labs is a company that creates solutions to prevent the sixth mass extinction by harnessing the democratization of science and technology, and scaling through the private sector, partnerships with conservation organizations, and collabor...
DPRA Inc. is a Manhattan, KS-based company in the Business Services sector.